- Trials with a EudraCT protocol (893)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (2)
893 result(s) found for: Chemotherapy Agent.
Displaying page 1 of 45.
EudraCT Number: 2019-004682-40 | Sponsor Protocol Number: CBYL719K12301 | Start Date*: 2021-06-16 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: EPIK-O: A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single a... | |||||||||||||
Medical condition: Platinum-resistant or refractory, high-grade serous ovarian cancer with no germline BRCA mutation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Completed) PT (Completed) FI (Completed) CZ (Completed) DK (Completed) SK (Completed) FR (Completed) NL (Completed) ES (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004105-16 | Sponsor Protocol Number: MO29872 | Start Date*: 2017-12-11 | ||||||||||||||||||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | ||||||||||||||||||||||||||||
Full Title: A PHASE III, OPEN-LABEL, MULTICENTER, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB COMPARED WITH CHEMOTHERAPY IN PATIENTS WITH TREATMENT-NAÏVE ADVANCED OR RECURRENT (STAG... | ||||||||||||||||||||||||||||
Medical condition: Non-small cell lung cancer | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: DE (Completed) DK (Completed) CZ (Completed) GB (GB - no longer in EU/EEA) PT (Completed) PL (Completed) ES (Ongoing) IE (Completed) BE (Completed) SK (Completed) BG (Completed) IT (Ongoing) RO (Ongoing) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002932-18 | Sponsor Protocol Number: 42756493-BLC3001 | Start Date*: 2018-02-08 | |||||||||||
Sponsor Name:Janssen-Cilag International NV | |||||||||||||
Full Title: A Phase 3 Study of Erdafitinib Compared with Vinflunine or Docetaxel or Pembrolizumab in Subjects with Advanced Urothelial Cancer and Selected FGFR Gene Aberrations | |||||||||||||
Medical condition: Advanced Urothelial Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Trial now transitioned) HU (Completed) ES (Ongoing) AT (Completed) FR (Trial now transitioned) DE (Ongoing) NL (Ongoing) PT (Ongoing) GR (Ongoing) PL (Completed) IT (Ongoing) DK (Ongoing) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001944-21 | Sponsor Protocol Number: PALO-03-14 | Start Date*: 2005-09-23 |
Sponsor Name:Helsinn Healthcare SA | ||
Full Title: Multicenter, Phase III, Open-Label, Uncontrolled Study to Assess the Safety and Efficacy of a Single Oral Dose of Palonosetron 0.75 mg in the Prevention of Chemotherapy Induced Nausea and Vomiting ... | ||
Medical condition: Moderately emetogenic chemotherapy induced nausea and vomiting | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005003-41 | Sponsor Protocol Number: 392MD/15/C | Start Date*: Information not available in EudraCT |
Sponsor Name:Strakan Pharmaceuticals Ltd | ||
Full Title: A randomised, active control, double-blind, double-dummy, parallel-group, multi-national study to assess the efficacy, tolerability and safety of the granisetron transdermal delivery system (GTDS) ... | ||
Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with the administration of moderately or highly emetogenic multi-day chemotherapy. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Prematurely Ended) CZ (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-003755-12 | Sponsor Protocol Number: | Start Date*: 2006-10-24 |
Sponsor Name:Hull & East Yorkshire NHS Trust | ||
Full Title: A Randomised Phase III Study in Advanced Oesophageal Cancer to compare Quality of Life and Palliation of Dysphagia in Patients Treated with Radiotherapy versus Chemo-radiotherapy. | ||
Medical condition: Advanced oesophageal cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2016-000227-71 | Sponsor Protocol Number: ITCC-059 | Start Date*: 2016-09-02 | |||||||||||
Sponsor Name:Erasmus Medical Center | |||||||||||||
Full Title: A phase I/II study of Inotuzumab Ozogamicin as a single agent and in combination with chemotherapy for pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia | |||||||||||||
Medical condition: pediatric CD22-positive relapsed/refractory Acute Lymphoblastic Leukemia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Trial now transitioned) DE (Trial now transitioned) IE (Trial now transitioned) AT (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) ES (Ongoing) CZ (Ongoing) GB (GB - no longer in EU/EEA) FR (Ongoing) IT (Ongoing) NO (Trial now transitioned) FI (Trial now transitioned) PT (Ongoing) BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-003564-72 | Sponsor Protocol Number: | Start Date*: 2012-01-13 |
Sponsor Name:Aarhus University Hospital [...] | ||
Full Title: A Randomised phase II study with the combination of Xeloda (Capecitabine) plus Navelbine Oral ( Vinorelbine) day 1 and day 8 every 3. week versus Xeloda plus Navelbine Oral given metronimic as 1. o... | ||
Medical condition: Patient with relapse of breast cancer will be randomised for two different chemotherapy regimes ( 2 treatments arms) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2014-001783-34 | Sponsor Protocol Number: MK-0517-044 | Start Date*: 2015-08-05 |
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | ||
Full Title: A phase III, randomized, placebo-controlled clinical trial to study the efficacy and safety of MK-0517/fosaprepitant and ondansetron versus ondansetron for the prevention of chemotherapy-induced na... | ||
Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: SE (Completed) NO (Completed) ES (Completed) LT (Completed) FI (Completed) PT (Completed) EE (Completed) HU (Completed) GB (Completed) NL (Completed) GR (Completed) Outside EU/EEA | ||
Trial results: View results |
EudraCT Number: 2009-011251-48 | Sponsor Protocol Number: CNTO888PCR2001 | Start Date*: 2009-08-28 | |||||||||||
Sponsor Name:Janssen Biologics B.V. | |||||||||||||
Full Title: An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects with Metastatic Castrate-Resistant Prostate Cancer | |||||||||||||
Medical condition: Metastatic Castrate-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018780-42 | Sponsor Protocol Number: OMB113676 | Start Date*: 2010-10-28 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: Phase III Randomized, Open Label Study of Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy | ||
Medical condition: Indolent B-Cell Non-Hodgkin's Lymphoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SK (Completed) CZ (Prematurely Ended) BG (Prematurely Ended) BE (Completed) FR (Completed) HU (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002340-24 | Sponsor Protocol Number: 0517-029 | Start Date*: 2012-10-26 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for... | |||||||||||||
Medical condition: Chemotherapy-induced nausea and vomiting (CINV) associated with emetogenic chemotherapy | |||||||||||||
|
|||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) PT (Completed) DE (Completed) AT (Completed) HU (Completed) EE (Completed) GB (Completed) LT (Completed) GR (Completed) IT (Completed) RO (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006259-12 | Sponsor Protocol Number: 1814 | Start Date*: 2012-09-03 | |||||||||||
Sponsor Name:Jules Bordet Institute | |||||||||||||
Full Title: Phase II study on prospective evaluating the quantification of total choline by magnetic resonance spectroscopy (MRS) in breast tumours as an early predictive marker of neoadjuvant chemotherapy res... | |||||||||||||
Medical condition: Early breast cancer requiring neoadjuvant chimiotherapy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2011-000651-16 | Sponsor Protocol Number: 0869-208 | Start Date*: 2011-07-20 | ||||||||||||||||
Sponsor Name:Merck Sharp & Dohme (Sweden) AB | ||||||||||||||||||
Full Title: A Phase III, Randomized, Double-Blind, Active Comparator-Controlled Clinical Trial, Conducted Under In-House Blinding Conditions, to Examine the Efficacy and Safety of Aprepitant for the Prevention... | ||||||||||||||||||
Medical condition: Pediatric Chemotherapy induced nausea and vomiting (CINV) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) PT (Not Authorised) LT (Completed) ES (Completed) NL (Completed) DK (Completed) HU (Completed) SI (Completed) GR (Completed) GB (Completed) IT (Completed) Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002417-36 | Sponsor Protocol Number: CAPTEM | Start Date*: 2014-08-28 | ||||||||||||||||
Sponsor Name:Fondazione IRCCS Istituto Nazionale dei Tumori | ||||||||||||||||||
Full Title: An open-label, randomized, multicenter, phase II trial designed to estimate the activity of CAPTEM combination versus FOLFIRI as second line treatment in patients who have progressed on or after fi... | ||||||||||||||||||
Medical condition: colorectal cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-005816-29 | Sponsor Protocol Number: 2006-002-0201-ONC | Start Date*: 2008-06-17 |
Sponsor Name:Royal Wolverhampton Hospitals Trust | ||
Full Title: A Pilot Study of Taxotere (Docetaxel), Cisplatin and 5FU (TPF) in the Palliative Treatment of Squamous Cell Carcinoma of the Head and Neck | ||
Medical condition: Locally recurrent or metastatic squamous call carcinoma of the head and neck | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-000080-16 | Sponsor Protocol Number: NeoToc | Start Date*: 2016-07-21 | |||||||||||
Sponsor Name:Vejle Hospital | |||||||||||||
Full Title: Tocotrienol in combination with neoadjuvant chemotherapy for women with breast cancer | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-012595-27 | Sponsor Protocol Number: A8081007 | Start Date*: 2010-01-20 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017 | |||||||||||||
Full Title: PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF THE EFFICACY AND SAFETY OF PF 02341066 VERSUS STANDARD OF CARE CHEMOTHERAPY (PEMETREXED OR DOCETAXEL) IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (... | |||||||||||||
Medical condition: ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) HARBORING A TRANSLOCATION OR INVERSION EVENT INVOLVING THE ANAPLASTIC LYMPHOMA KINASE (ALK) GENE LOCUS | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) NL (Completed) DE (Completed) PL (Completed) ES (Completed) HU (Completed) FR (Completed) GR (Completed) IT (Completed) IE (Completed) BG (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-002767-17 | Sponsor Protocol Number: D0816C00020 | Start Date*: 2017-12-14 | |||||||||||
Sponsor Name:AstraZeneca AB | |||||||||||||
Full Title: A Phase IIIb, Single-arm, Open-label Multicentre Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed non-Germline BRCA Mutated Ovarian Cancer Patients who are in Complete or Pa... | |||||||||||||
Medical condition: Non Germline BRCA Mutated Ovarian Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: CZ (Completed) SI (Completed) BG (Completed) GB (GB - no longer in EU/EEA) NL (Completed) ES (Completed) BE (Completed) AT (Completed) SE (Completed) PT (Completed) NO (Completed) DK (Completed) FI (Completed) PL (Completed) IT (Completed) RO (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002919-18 | Sponsor Protocol Number: AC220-A-U202 | Start Date*: Information not available in EudraCT | |||||||||||||||||||||
Sponsor Name:Daiichi Sankyo, Inc. | |||||||||||||||||||||||
Full Title: A Phase 1/2, Multicenter, Dose-Escalating Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy Of Quizartinib Administered in Combination with Re-Induction Chemotherapy, a... | |||||||||||||||||||||||
Medical condition: Relapsed or Refractory acute myeloid leukemia (AML) in subjects aged ≥1 month to ≤21 years with FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) mutations following failure of fr... | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IE (Prematurely Ended) FR (Ongoing) DK (Trial now transitioned) ES (Ongoing) BE (Trial now transitioned) SE (Ongoing) NL (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Ongoing) | |||||||||||||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.